Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences. Pulmonx management is scheduled to participate in the 2022 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7, 2022, at 6:10am PT / 9:10am ET and the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Tuesday, September 13, 2022, at 1:40pm PT / 4:40pm ET.

A live and archived webcast of the presentations will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005508/en/

Brian Johnston
Gilmartin Group
[email protected]

Source: Pulmonx Corporation

You May Also Be Interested In

• SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile
• Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Record Q2 Revenue, EAI Robotics Entering a Phase of Positive-Gross-Margin Volume Growth, and Accelerated Debt Reduction